As at November 30, 2007, the Company's cash and cash equivalents, short-term investments and working capital position were $5,635,365, $6,825,190 and $9,088,712 respectively, compared with November 30, 2006 balances of $4,077,065, $16,135,490 and $20,222,321, respectively. The Company believes that it has adequate financial resources for anticipated expenditures until the fourth quarter of fiscal 2008.
ARIUS will host a conference call today (Tuesday January 29, 2008 at 8:00 a.m. ET) to discuss its fourth quarter and year-end fiscal 2007 results. To access the conference call by telephone, dial 416-644-3414 or 1-800-731-6941. Please connect approximately five minutes prior to the beginning of the call to ensure participation. A live audio webcast of the conference call will be available at http://www.ariusmabs.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above website for 365 days.
ARIUS is a biotechnology company discovering and developing the next
wave of antibody therapeutics. Established in 1999, ARIUS has built a
proprietary technology platform, FunctionFIRST(TM), that rapidly identifies
and selects antibodies based on their functional ability to affect disease.
This antibody generation engine has enabled ARIUS to assemble a portfolio
of more than 500 antibody candidates. In addition to the antibodies it is
developing in-house, ARIUS has ongoing partnerships with key biotechnology
and drug development companies. ARIUS is listed on the TSX under the symbol
"ARI". For further information, visit http://www.ariusmabs.com
Financial Information to follow:
ARIUS RESEARCH INC.
(A DEVELOPMENT STAGE COMPANY)
|SOURCE ARIUS Research Inc.|
Copyright©2008 PR Newswire.
All rights reserved